Browse
Submit Data
Databases
API
Help

Dataset Information

19 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RASTRIC-trial: investigating the safety and efficacy of a new three drug treatment combination for RAS-mutated metastastic colorectal cancer.

ABSTRACT: Primary objectives: Phase I The main objective of the phase I part is to determine safety and the recommended phase II dose (RP2D) of the triple combination. Phase II The main objective of the phase II part is to determine efficacy of the triplet combination defined by objective response rate according to RECIST 1.1. Primary endpoints: For the phase I dose-escalation trial: The primary endpoint is the incidence of DLTs leading to a RP2D. The RP2D of the triplet will be the MTD which is defined as the dose level that can be given to 6 subjects such that not more than 1 subject experiences a DLT. For the phase II trial: The primary endpoint is best overall response (OR), defined as complete response (CR) + partial response (PR) within 6 months, based on RECIST 1.1.

DISEASE(S): Colorectal Cancer,Colorectaal Carcinoom

PROVIDER: 2539846 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

RASTRIC-trial: onderzoek naar de veiligheid en effectiviteit van een nieuwe behandeling met drie middelen voor patiënten met uitgezaaide dikkedarmkanker met een RAS-mutatie.

Project description:Interventions: lapatinib + binimetinib + vinorelbine Primary Objective: Phase I dose escalation The main objective of the phase I part is to determine safety and the recommended phase II dose (RP2D) of the triple combination. Phase II The main objective of the phase II part is to determine efficacy of the triplet combination defined by objective response rate according to RECIST 1.1. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Other

| 2443226 | ecrin-mdr-crc

A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and anticancer activity of GLG-801 in patients with Metastatic TNBC (Phase II).

Project description:Primary objectives: Phase I• To evaluate safety and tolerability of escalating dose levels of GLG-801 in adult patients with advanced, refractory, solid tumors.• To determine RP2D based on MTD. Phase II• To determine the response (radiologic ORR), in patients with metastatic TNBC (based on Recist 1.1. Criteria) • To confirm the safety and tolerability of GLG-801 in patients with advanced TNBC at RP2D as determined in Phase I portion of this study. Primary endpoints: Phase I1. Evaluation of safety and tolerability (% dropout) of escalating dose levels of GLG-8012. Determination of RP2D based on MTDPhase II1. Determination of the response (radiologic ORR), in patients with metastatic TNBC (based on Recist 1.1. Criteria) 2. Confirmation of the safety and tolerability of GLG-801 in patients with advanced TNBC, at RP2D as determined in Phase I portion of this study

| 2537689 | ecrin-mdr-crc

Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial

Project description:Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib-nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). ORR per RECIST version 1.1 was 31.0%, meeting the primary endpoint. The most common adverse events were palmar-plantar erythrodysesthesia syndrome (38.1%), alopecia (26.2%) and skin rash (23.8%). Median PFS was 7.38 months. The 1-year OS rate was 80.5%, and the median OS was not reached. Exploratory single-cell RNA sequencing analyses of peripheral blood mononuclear cells showed that long-term responders exhibited T cell receptor repertoire diversification, enrichment of genes representing immunotherapy responsiveness in MKI67+ proliferating CD8+ T cells and a higher probability of M1-directed monocyte polarization. Our data support further clinical development of the regorafenib-nivolumab combination as front-line treatment for uHCC and provide preliminary insights on immune biomarkers of response. ClinicalTrials.gov identifier: NCT04310709 .

2023-12-31 | GSE243572 | GEO

A study to evaluate CM24 in combination with nivolumab in adults with solid tumours

Project description:Primary objectives: Part A• To assess the safety, tolerability and the maximum tolerated dose (MTD) of CM24 in combination with 480mg nivolumab in adults with selected recurrent or metastatic solid tumors.• Determine the recommended Phase 2 dose level (RP2D) of CM24 in combination with nivolumab Part BTo assess the efficacy of the recommended phase 2 dose (RP2D) of CM24 in combination with nivolumab in adults with immune-checkpoint refractory recurrent or metastatic NSCLC based on Objective Response Rate (ORR). Part CTo assess the efficacy of CM24 in combination with nivolumab and nabpaclitaxel in adults with metastatic pancreatic cancer based on Objective Response Rate. Primary endpoints: Part ASafety and tolerability Parts B and CObjective response rate (ORR) based on RECIST Version 1.1

| 2540836 | ecrin-mdr-crc

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.

Project description:KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We investigated the in vitro and in vivo preclinical activity of KW-2450 plus lapatinib and letrozole and conducted a phase I trial of the triple-drug combination in one male and 10 postmenopausal female patients with advanced/metastatic hormone receptorpositive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A series of in vitro and in vivo animal studies was undertaken of KW-2450 in combination with lapatinib and hormonal agents. The phase I trial was conducted to establish the safety, tolerability, and recommended phase II dose (RP2D) of KW-2450 administered in combination with lapatinib and letrozole. Preclinical studies showed KW-2450 and lapatinib act synergistically to induce in vitro apoptosis and inhibit growth of HER2-positive MDA-MB-361 and BT-474 breast cancer cell lines. This combined effect was confirmed in vivo using the MDA-MB-361 xenograft model. KW-2450 showed synergistic in vitro growth inhibition with letrozole and 4-hydroxytamoxifen in ER-positive MCF-7 breast cancer cells and MCF-7-Ac1 aromatase-transfected MCF-7 cells. In the phase I study, dose-limiting toxicity (DLT; grade 3 rash and grade 3 hyperglycemia, respectively) occurred in two of three patients at the dose of KW-2450 25 mg/day plus lapatinib 1500 mg/day and letrozole 2.5 mg/day. The RP2D of the triple-drug combination was established as KW-2450 25 mg/day, lapatinib 1250 mg/day, and letrozole 2.5 mg/day with no DLT at this dose level.

2018-08-26 | GSE82161 | GEO

A clinical study to evaluate the safety, tolerability, and efficacy of INCB001158 in combination with chemotherapy in subjects with advanced or metastatic solid tumors.

Project description:Primary objectives: • Phase 1: To assess the safety and tolerability and determine the recommended Phase 2 dose (RP2D) of INCB001158 in combination with chemotherapy. • Phase 2: To evaluate the objective response rate (ORR) of INCB001158 in combination with chemotherapy. Primary endpoints: • Phase 1: Safety, tolerability, dose-limiting toxicities (DLTs), and RP2D of INCB001158 in combination with chemotherapy, as assessed by adverse events (AEs), clinical laboratory tests, physical examination results, and 12-lead electrocardiogram (ECG) results. • Phase 2: ORR, defined as the percentage of subjects having a complete response (CR) or partial response (PR), as determined by investigator assessment of radiographic disease as per RECIST v1.1.

| 2537194 | ecrin-mdr-crc

First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Project description:Primary objectives: Phase I:Characterize the safety, tolerability and immunogenicity of IN01 in combination with a small molecule inhibitor to confirm the recommended Phase II treatment dose and schedule Phase II:Further assess the efficacy in the different selected mCRC genotypes based on tumour response, biomarkers and survival. Some biomarker collection and/or analysis may be limited to selected sites and patients Primary endpoints: Phase I:• Proportion of patients achieving an anti-EGF antibody immune response• Dose limiting toxicity rates Phase II:Objective response rate (ORR: complete and partial responses) according to RECIST 1.1

| 2539812 | ecrin-mdr-crc

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Project description:The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) or of E7386 in combination with pembrolizumab plus lenvatinib (HCC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

| 2393260 | ecrin-mdr-crc

Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study.

Project description:Primary objectives: To determine the objective response rate (ORR) according to RECIST 1.1 criteria in order to assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers Primary endpoints: Efficacy of pembrolizumab will be measured by the objective response rate (ORR) according to RECIST 1.1 criteria. The ORR (%) is defined as the proportion of patients with complete response (CR) or partial response (PR) according to RECIST 1.1 as the best observed response to pembrolizumab treatment. All subjects who were treated with at least one cycle of pembrolizumab and underwent subsequent evaluation of their disease will be considered evaluable for response.

| 2756173 | ecrin-mdr-crc

Efficacy of trametinib and dabrafenib associated with radioactive iodine for the treatment of refractory metastatic differentiated thyroid cancer

Project description:Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation. To evaluate the objective response rate according to RECIST criteria in thyroid cancer patients with metastatic radioactive iodine (RAI) refractory disease, 6 months after a treatment combining in each arm of the phase II trial (patients with RAS mutation or patients with BRAFV600E mutation): - Arm A: 6 weeks of trametinib followed by RAI treatment (5.5 GBq following rhTSH) in patients with RAS mutation - Arm B: 6 weeks of trametinib plus dabrafenib followed by RAI treatment (5.5 GBq following rhTSH) in patients with BRAFV600E mutation

2023-09-01 | E-MTAB-12837 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data